- Home
- ZBAI vs LYRA Comparison
ZBAI vs LYRA Comparison
Compare ZBAI & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZBAI | LYRA |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7M | 7.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ZBAI | LYRA |
|---|---|---|
| Price | $7.95 | $3.86 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 6.0K | ★ 91.7K |
| Earning Date | 12-15-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,200,000.00 | $600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $93.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 93.55 | N/A |
| 52 Week Low | $4.83 | $2.84 |
| 52 Week High | $45.00 | $37.50 |
Technical Indicators
Market Signals| Indicator | ZBAI | LYRA |
|---|---|---|
| Relative Strength Index (RSI) | 59.13 | 43.57 |
| Support Level | $6.66 | $3.55 |
| Resistance Level | $6.91 | $4.15 |
| Average True Range (ATR) | 0.38 | 0.48 |
| MACD | 0.15 | 0.11 |
| Stochastic Oscillator | 96.87 | 58.29 |
Price Performance
Historical ComparisonAbout ZBAI ATIF Holdings Limited Ordinary Shares
ATIF Holdings Ltd is a consulting company. It provides financial consulting services to small and medium-sized enterprises. It operates in one operating segment, which is the consulting service business. The company prominently generated revenues from consulting services to its clients. Geographically, the maximum revenue is derived from Hong Kong.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.